AZ-AXWAY
30.11.2022 08:01:52 CET | Business Wire | Press release
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, today announced new data from its inaugural 2022 Open Everything Strategy Survey Report. Polling nearly 1,000 IT leaders, architects, and developers about their digital strategies and top concerns, the survey found nearly 40% of organizations are in the process of adopting a new hybrid approach for their IT infrastructure. The transformation comes as 68% of respondents cite their fears about API sprawl.
The survey data reflects responses from those engaged primarily in API development (893) and managed file transfer (MFT) services (102). Ensuring data security and controlling API sprawl were top concerns, with over two-thirds (68%) worrying about complexity due to sprawl and almost half (48%) of respondents ranking “increased security challenges” as their single greatest concern with API growth. Respondents again cited security as far and away the most important criteria when creating an API (30% among API respondents) and when setting up a new MFT service (48% among MFT respondents).
“Enterprises are in the thick of digital transformation and accompanying cloud and data migrations have made it possible to free up data so it can be exchanged, reused and remixed to fuel innovation and business growth. But that’s messy,” said Vince Padua, Chief Innovation and Technology Officer at Axway. “It brings complexity and security challenges that must be answered by using truly universal API management—that bridges the gap between API development and consumption and opens everything, lines of business and innovation, while building on and out from heritage infrastructure.”
The survey results indicate that budgets for API management have increased over the past two years and that security is top of mind as companies begin to unlock the full value of their data to create new digital experiences, markets and opportunities for revenue. Half of those surveyed reported modestly elevated API management budgets, with about 34% of respondents seeing increases up to 25%. Less than 20% of respondents saw budget decreases.
Drilling down further into security strategy and the impending skills gap
Digging deeper, the survey found that a significant majority, 59%, employ user authentication as a top strategy to secure APIs, and almost two-thirds of the API respondents (61%) said data encryption can help them personally feel their data is more secure. They also cited developing a more holistic approach to security as the number one strategy for protecting personal data.
When a member logs into our online channels or walks into one of our branches, we want to personalize their experience in real time. To achieve this, we targeted a high-performance API integration layer,” said Ravi Peru, Chief Information Officer at Community America Credit Union.
"When you have more than 50 products, handling integration in an agile way is very important," added Peru. "With Axway, we can interface with anything and move data between any internal systems we want. That would be really slow with point-to-point integration, but Axway makes it quick and easy."
Security factors into cloud strategy as well. Among the most significant challenges inhibiting cloud strategy, according to respondents, are:
- 53% – Dealing with different security requirements for regional instances of cloud infra
- 55% – Tracking and controlling the flow of personal data into and through the cloud
One of the most alarming, but not entirely surprising data points, deals with concerns about talent: 86% of API respondents fear an expertise gap in the coming years, where companies will not have the skilled software and IT infrastructure talent they need to innovate.
Click here to see the full report.
Survey Methodology
The 2022 Open Everything Strategy Survey was conducted between July 21 and August 16 of 2022 among two similar, but divided subsets of respondents: API development and MFT integration professionals. Axway engaged in direct email outreach among its contacts with opt-in email addresses, and received nearly 1,000 responses, including 893 from those in API development and 102 in MFT services, from various locations throughout the world.
About Axway
Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006117/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
